

1 **Higher Perceived Stress during the COVID-19 pandemic increased Menstrual**
2 **Dysregulation and Menopause Symptoms**
3
4

5 Romina Garcia de Leon¹, Alexandra Baaske², Arianne Y Albert² PhD, Amy Booth^{2,6}, C.
6 Sarai Racey^{2,6}, Shanlea Gordon², Laurie W. Smith, Anna Gottschlich^{2, 6}, Manish
7 Sadarangani^{4,5} MD, Angela Kaida^{2,3} PhD, Gina S. Ogilvie^{2,6} MD, Lori A. Brotto^{2,7,*} PhD,
8 Liisa A.M. Galea^{1,8,9} PhD

9 ¹Graduate Program in Neuroscience, University of British Columbia, Vancouver,
10 Canada.

11 ²Women's Health Research Institute, Vancouver, Canada

12 ³Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

13 ⁴Department of Pediatrics, University of British Columbia, Vancouver, Canada.

14 ⁵Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver,
15 Canada.

16 ⁶School of Population and Public Health, University of British Columbia, Vancouver,
17 Canada.

18 ⁷Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver,
19 Canada.

20 ⁸Department of Psychology, University of British Columbia, Vancouver, Canada.

21 ⁹Djavad Mowafaghian Centre for Brain Health, University of British Columbia
22 & Department of Pathology and Laboratory Medicine, University of British Columbia,
23 Vancouver, Canada.

24

25

26

27 *Correspondence can be addressed to:

28 Dr. Liisa Galea

29 Djavad Mowafaghian Centre for Brain Health

30 University of British Columbia

31 2215 Wesbrook Mall

32 Vancouver, BC, Canada

33 V6T 1Z3

34 liisa.galea@ubc.ca

35

36

37
38
39
40
41
42
43
44
45
46
47
48
49
50

51

52
53
54

55
56
57
58
59
60
61
62
63
64
65

Statements and Declarations

Funding: Funding for this project was from a Michael Smith Foundation for Health Research Grant (19055) and a BC Women's Health Foundation Grant (LRZ30421) both awarded to LAB and GSO. Additional support was provided by CIHR (PJT-148662) awarded to LAMG.

Competing Interests The authors have no competing interests to declare that are relevant to the content of this article.

Ethical Approval Ethical approval was received from the BC Children's and Women's Research Ethics board (H20-01421). All methods performed as a part of this study were in accordance with the UBC Research Ethics Board guidelines.

Informed consent to participate was obtained from participants.

Data Availability Data cannot be shared publicly because of ethical restrictions. Data are available from the UBC Research Ethics Board (contact via cwreb@bcchr.ubc.ca) for researchers who meet the criteria for access to confidential data.

Author Contributions: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Arianne Albert, Amy Booth, Shanlea Gordon, Alexandra Baaske and Romina Garcia de Leon. The first draft of the manuscript was written by Romina Garcia de Leon, Alexandra Baaske, and Liisa Galea and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Acknowledgements We thank David M. Goldfarb and Melanie Murray for their contributions to this work.

Abstract

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109

Purpose

The increased stress the globe has experienced with the COVID-19 pandemic has affected mental health, disproportionately affecting women. However, how perceived stress in the first year affected menstrual and menopausal symptoms has not yet been investigated.

Methods Residents in British Columbia, Canada, were surveyed online as part of the COVID-19 Rapid Evidence Study of a Provincial Population-Based Cohort for Gender and Sex (RESPONSE). A subgroup (n=4171) who were assigned female sex at birth (age 25-69) and were surveyed within the first 6-12 months of the pandemic (August 2020-February 2021), prior to the widespread rollout of vaccines, were retrospectively asked if they noticed changes in their menstrual or menopausal symptoms, as well as completing validated measures of stress, depression, and anxiety.

Results We found that 27.8% reported menstrual cycle disturbances and 6.7% reported increased menopause symptoms. Those who scored higher on perceived stress, depression, and anxiety scales were more likely to have reproductive cycle disturbances. Free text responses revealed that reasons for disturbances were perceived to be related to the pandemic.

Conclusions The COVID-19 pandemic has highlighted the need to research women's health issues, such as menstruation. Our data indicates that in the first year of the pandemic, almost a third of the menstruating population reported disturbances in their cycle, which is approximately two times higher than in non-pandemic situations and four times higher than any reported changes in menopausal symptoms across that first year of the pandemic.

Keywords anxiety; depression; women; reproductive cycles; stress; COVID-19

110 The COVID-19 pandemic led to closures of public places, strict health
111 regulations, and limited social interactions. These changes, along with the uncertainty of
112 the pandemic, resulted in increased perceived levels of stress, depression, and anxiety
113 (Brotto et al., 2021; Kujawa et al., 2020). Women and gender diverse individuals
114 exhibited greater indices of distress, including heightened risk for mental health
115 disorders than men throughout the COVID-19 pandemic (Brotto et al., 2021; Connor et
116 al., 2020; Hunt et al., 2021).

117 Despite these findings, there has been minimal attention paid to the effects of
118 sex and gender in COVID-19 studies (Brady et al., 2021; Ciarambino et al., 2021;
119 Edelman et al., 2022). There has been a lack of research on the specific impact of
120 SARS-CoV-2 vaccines, and pandemic response on female health (Sharp et al., 2021)
121 which has contributed to alarming anecdotal reports of menstrual cycle irregularities
122 following COVID-19 vaccination on social media (Male, 2021). These reported incidents
123 underscored the importance of studying female cycles, which are now being closely
124 examined in relation to COVID-19 vaccination (Edelman et al., 2022; Lee et al., 2021;
125 Trogstad, 2022). However, there remains a need to examine the overall impact of the
126 pandemic response on female menstrual cycles.

127 Menstrual cycle irregularities, perimenopause, and menopausal disturbances can
128 be important indicators of overall physical health (Alvergne & Högqvist Tabor, 2018).
129 Menstrual cycle irregularity is linked to metabolic dysfunction (Souza et al., 2010) and
130 increased risk of cardiovascular disease (Solomon et al., 2002). Furthermore,
131 vasomotor menopausal symptoms are related to white matter hyperintensities and
132 cognitive disturbances (Thurston et al., 2016). Exposure to stress affects the
133 hypothalamic pituitary gonadal (HPG) axes (Viau, 2002) as higher perceived stress is
134 correlated with menopausal symptoms (Nosek et al., 2010; Weidner et al., 2020) and
135 menstrual dysregulation (Nagma et al., 2015).

136 Thus, it is not surprising that the COVID-19 pandemic and the associated
137 increase in stress has led to reports of disturbances to menstrual cycles (Phelan et al.,
138 2021). Premenopausal people have reported irregularities in their menstrual cycles
139 across different phases of the COVID-19 pandemic (Demir et al., 2021), consistent with
140 the literature indicating that heightened perceived stress is a predictor for menstrual

141 irregularities (Yamamoto et al., 2009). Prolonged stress is also associated with an
142 increased risk for psychiatric disorders (McEwen & Akil, 2020) and females reported
143 higher depressive symptoms than males during the COVID-19 pandemic (Brotto et al.,
144 2021; Pieh et al., 2020). Moreover, studies show that depressed mood is associated
145 with menstrual irregularities (Yu et al., 2017), meaning that pandemic-related stress
146 may be affecting mental health and menstrual irregularities simultaneously or
147 sequentially. Given that stress and menstrual irregularities are connected (Yamamoto et
148 al., 2009), and may play a role in mental health disturbances (Yu et al., 2017), it is
149 important to study these relationships.

150 Heightened stress would likely have an impact on menstrual/menopausal
151 irregularities, but to our knowledge no study to date has examined these irregularities in
152 relation to psychosocial outcomes such as perceived stress, anxiety, or depression
153 scores, and other factors that may play a role in perceived stress (age, number of
154 children) within the context of the COVID-19 pandemic. We hypothesized that females
155 would report an increase in the number of menstrual and menopausal symptoms during
156 the first year of the pandemic, and secondly that these disturbances would be
157 associated with stress, anxiety and depression levels.

158

159 **Methods**

160 **Participant Recruitment**

161 The Rapid Evidence Study of a Provincial Population Based COhort for GeNder and
162 SEx (RESPPONSE) was led by the Women's Health Research Institute in British
163 Columbia (BC). All participants provided informed consent prior to participation in
164 RESPONSE. Ethics approval was received from The BC Children's and Women's
165 Research Ethics Board (H20-01421). Between mid-August 2020 and March 1, 2021,
166 participants were recruited (Ogilvie et al., 2021). Survey responses were collected
167 anonymously, with the exception of postal code. All respondents who completed the
168 survey were invited to enter a draw to win a \$100 e-gift card.

169 The survey was open to residents of BC aged 25 to 69 years of all sexes and genders.
170 However, only participants who were assigned female sex at birth were eligible for this

171 particular analysis (n=5608). For analyses pertaining to menstrual changes, eligibility
172 was restricted to: female sex, not post-menopausal, not pregnant, first six months
173 postpartum, and not on hormonal suppression drugs (n=1866). In addition, we also
174 conducted sensitivity analyses for menstrual changes to those people under 40 to avoid
175 conflation with possible symptoms of perimenopause (n=810). For analyses of
176 menopausal symptoms, eligibility was restricted to female sex and those who
177 responded that they were postmenopausal (n=2305). In addition, we also conducted
178 sensitivity analyses for menopause status to those people over 50 (n=1978) to avoid
179 conflation with possible symptoms of perimenopause.

180 **Survey Design and Measures**

181 The survey was tested for face validity, pilot tested, and implemented using
182 REDCap (Research Electronic Data Capture) (Harris et al., 2009). The survey consisted
183 of multiple modules, with the present analysis focused on female reproductive health
184 questions surrounding menstrual cycle and menopause symptoms.

185 All survey participants that were premenopausal were asked "Since the COVID-
186 19 pandemic and subsequent public health measures in mid-March 2020, have you
187 noticed any changes to your menstrual cycle? (yes/no/not applicable due to hormonal
188 suppression/not applicable other)", and participants that were postmenopausal were
189 asked "Have you noticed any changes to your postmenopausal status since mid-March
190 2020? (yes/no)." Respondents who indicated changes to their menstrual cycle or
191 postmenopausal status were prompted to check all that applied from a list of changes
192 and provided with a free-text box (Survey available in Supplemental Section). All free-
193 text responses were coded with thematic analysis using the methods outlined in Braun
194 & Clarke (2006) to examine the potential variables influencing these changes. All
195 responses were assigned to one of two main themes: 'Non-pandemic related' and
196 'Pandemic control measures.' "Non-pandemic related" comments were obvious
197 changes to their health and reproductive system at the start of the pandemic or
198 preceding the pandemic. Alternatively, specific mentions of changes to their status or
199 cycle, without medical reason, and stated as due to the pandemic were categorized as
200 pandemic-related. After separating all responses into these two themes, sub-themes

201 were created to identify reproductive changes that occurred during the pandemic. Sub-
202 themes were created if one or more respondents expressed the same theme in their
203 free-text response.

204 Validated scores of general pandemic stress, anxiety, and depression were
205 measured (Huang et al., 2006; Löwe et al., 2008). General pandemic stress was
206 measured using the CoRonavlrus Health Impact Survey (CRISIS) V0.3. Participants
207 were asked to self-report feelings of stress on a Likert scale from one (not at all) to five
208 (extremely). Scores for this questionnaire range from 10–50 with higher scores
209 indicating greater COVID-related stress.

210 Anxiety scores were calculated using the Generalized Anxiety Disorder
211 questionnaire (GAD-7) The GAD-7 used self-reported feelings of anxiety on a Likert
212 scale from zero (not at all) to three (nearly everyday) with scores ranging from 0–21.
213 Scores above 10 suggest clinically significant levels of anxiety (Spitzer et al., 2006).

214 The Patient Health Questionnaire (PHQ-9) was used to measure self-reported
215 symptoms of depression on a Likert scale from zero (not at all) to three (nearly
216 everyday). Scores range from 0–27 with a score of 0–4 indicating minimal depression,
217 5–14 indicating mild to moderate depression and 15–27 indicating moderately severe to
218 severe depression (Brotto et al., 2021).

219 Internal consistency across data collection and Cronbach's alpha in the current
220 sample was very good (CRISIS: $\alpha = 0.882$; GAD-7: 0.889, PHQ: $\alpha = 0.848$).

221

222 **Statistical Analyses**

223 Analyses were carried out using R v.4.1.3. (Core Team, 2022). The data set was
224 divided into two separate groups: people with menstrual periods and those in
225 menopause (postmenopause) as described above and summarized the percentages of
226 those with any changes noted. We examined the relationship between mental health
227 and changes in menopause status or menstruation using mixed-effects linear
228 regression models with individual as random effects, and controlling for age.
229 Significance was assessed using likelihood-ratio tests, and interactions were removed
230 from the models if non-significant at $p < .05$. *Post-hoc pairwise tests were conducted to*

231 *further explore main or interaction effects with Tukey adjusted p-values.* Missing data
232 were excluded from analyses.

233

234 **Results**

235 **Survey Participants**

236 Demographic information (age, ethnicity, gender, number of adults or children in the
237 household, education, etc.) is seen in Table 1. Of the premenopausal participants,
238 98.4% identified as women, 0.1% identified as men and 1.5% as gender diverse. Of the
239 postmenopausal participants, 99% identified as women, 0.1% identified as men and
240 0.8% as gender diverse. Given that nearly all females also identified as women, we
241 have chosen to use the term women+ to refer to participants in our survey.

242

243 **Changes in menstrual symptoms**

244

245 Among our sample of premenopausal women+, 519 (27.8% of the sample without
246 suppressed cycles) reported that they had noticed changes in their menstrual cycle
247 since March 2020. Of these 519 respondents, 44.3% indicated that their periods were
248 more symptomatic (painful, more bleeding, etc.), 25.4%% indicated that their periods
249 were longer, 23.7%% said they were having fewer periods than before the pandemic,
250 21.8% noticed having more periods than normal, 15.7% said their periods had gotten
251 shorter, 2.3% said their periods were less symptomatic. Options were not mutually
252 exclusive and we received 784 answers from a potential 519 respondents. Moreover,
253 17.8% used free-text space to explain the changes to their menstrual cycles that they
254 had noticed. The analysis of the free text responses indicated that there were twice as
255 many respondents that indicated their changes in symptoms were due to the *Pandemic*
256 *control measures*(Table 2).

257

258 As those aged >40 years are more likely to be experiencing perimenopause, which
259 could create menstrual disturbances independent of psychosocial stress, we undertook
260 a sensitivity analysis of those who were less than 40 years old. Of this subset (n=810),
261 29.2% (n=237) reported changes in their menstrual cycle since the pandemic began. In

262 addition, 52.7% indicated that their periods were more symptomatic (painful, more
263 bleeding, etc.), 32.1% indicated that their periods had gotten longer, 13.1% said they
264 were having fewer periods than normal, 20.7% noticed having more periods than
265 normal, 19.0% said their periods had gotten shorter, 2.1% said their periods were less
266 symptomatic, and 19.8% used free-text space to explain the changes to their menstrual
267 cycles that they had noticed. Options were not mutually exclusive and we received 378
268 answers from a potential 237 respondents.

269

270 **Changes in menopausal symptoms**

271

272 Among our sample of postmenopausal females (n = 2305), 155 (6.7%) reported that
273 they noticed changes in their postmenopausal status since mid-March 2020. Of this
274 subset (n=155), 16.1% indicated that they started bleeding again and 12.3% indicated
275 that they were experiencing “more menstrual symptoms”. Additionally, 72.9% used free-
276 text space to explain the changes to their postmenopausal status. The analysis of the
277 free-text responses revealed that there were four times as many respondents that
278 indicated changes to postmenopausal status falling into the “due to the pandemic
279 control measures” category (Table 3).

280

281 As those aged <50 years are more likely to be experiencing perimenopause, which
282 could create menopausal disturbances independent of psychosocial stress, a sensitivity
283 analysis that restricted to those ≥50 (n = 1978) was conducted. Of this subset, there
284 were 127 (6.4%) who reported that they had noticed changes in their postmenopausal
285 status since before the pandemic. Of this subset (n=127), 18.1% indicated that they
286 started bleeding again and 7.9% indicated that they were experiencing “more menstrual
287 symptoms”. Additionally, 71.7% of this subset used free-text space to explain the
288 changes to their postmenopausal status that they had noticed. Analysis of these free-
289 text responses revealed that 19.8% of reported changes were associated with the onset
290 of the pandemic and 80.1% were not not pandemic-related.

291

292 **Higher pandemic stress, anxiety, and depression symptoms were related to**
293 **more disturbances in menstrual and menopausal symptoms**

294
295 We next examined whether any changes to menstrual or menopause symptoms were
296 related to anxiety, depression, or perceived stress. We found that across both groups,
297 more disturbances in their cycles indicated they scored higher on each of the
298 psychosocial measures, with premenopausal women+ scoring higher than
299 postmenopausal women+. For premenopausal women+ pandemic stress were 3.9
300 (95%CI:3.1-4.8) points higher, anxiety scores were 2.0 (95%CI: 1.6-2.4) points higher,
301 and depression scores were 2.4 (95%CI: 2.0-2.8) points higher on average in those that
302 reported menstrual cycle disturbances(Figure 1 A-C). For postmenopausal women+,
303 pandemic stress scores were 2.9 (95%CI: 1.9-3.9) points higher, anxiety scores were
304 1.5 (95%CI: 0.9-2.1) points higher, depression scores were 1.8 (95%CI: 1.2-2.5) points
305 higher on average in those that reported changes to their menopausal status (Figure
306 1D-F).

307 **Relationship of menstrual or postmenopausal disturbances to number of children** 308

309 As previous studies have found an association between number of children and stress
310 (Bigalke et al., 2020), we also examined whether the number of children influenced our
311 results. We ran these analyses in premenstrual women+ that were under 40, choosing
312 to exclude individuals who may have been perimenopausal based on age. There was
313 no significant relationship between the number of children and whether or not the
314 participant indicated they had disturbances to their menstrual cycle ($p=0.100$). We next
315 examined whether or not there was a relationship between menopausal disturbances
316 and the number of children. There was a significant relationship ($p=0.007$), however
317 when we used age as a covariate the effect was no longer significant ($p=0.409$). There
318 were also no significant relationships between the number of children and pandemic
319 stress scores, after controlling for age and changes to menstruation or menopause
320 ($p=0.167$ and 0.400 , respectively).

321

322

323 **Discussion**

324 In a sample of 4171 surveyed women+ in BC that met our inclusion criteria,
325 27.8% of naturally cycling women+ had a disruption in their menstrual cycle and 6.7% of

326 postmenopausal women+ indicated a change in their status, across the first year of the
327 COVID-19 pandemic and prior to widespread rollout of COVID-19 vaccines. These
328 disturbances to the reproductive cycles were related to higher levels of anxiety,
329 depression, and perceived stress, but not to the number of children, in both pre and
330 postmenopausal women+. Premenopausal women+ with menstrual cycle phase
331 disturbances scored higher on perceived stress (3.4 points), anxiety (2.0) and
332 depression (2.4) measures. We previously found that women had higher levels of
333 perceived stress, depression, and anxiety compared to men, using data from the same
334 source (Brotto et al., 2021). Our findings here indicate that both pre and
335 postmenopausal women+ with higher levels of mental distress experienced greater
336 disturbances in reproductive cycles. Stress has pervasive effects on mental and
337 physical health and our results add to the growing data that female-specific reproductive
338 cycles are also affected.

339

340 *During the first year of the pandemic menstrual cycle disturbances were related to*
341 *distress, anxiety and depression.*

342 We found that in the first year of the pandemic, 27.8% of the naturally-cycling
343 women+ surveyed had disturbances to their menstrual cycles. This is slightly lower than
344 other surveys suggesting that 44% of women (including women that were younger than
345 our own cohort 18-24) noticed changes in their cycles using fertility tracking devices
346 (Buran & Gerçek Öter, 2022; Haile et al., 2022). Other studies have suggested that the
347 baseline rates of menstrual disturbances are ~15% (Toffel et al., 2013, Kim et al., 2018).
348 Premenopausal women in our study with reported menstrual disturbances had 3.4 times
349 higher perceived stress. Our findings are consistent with another study that showed an
350 association between perceived stress during the COVID-19 pandemic and menstrual
351 irregularities (Ozimek et al., 2022). Although the literature suggests that parental
352 responsibility increases perceived stress in women compared to men (Bigalke et al.,
353 2020), we found no evidence that there was a significant relationship between the
354 number of children, and changes in the menstrual cycle or in perceived stress in
355 women+ younger than 40. Our data also indicate that anxiety scores were 2 points

356 higher and depression scores were 2.4 points higher on average in those that reported
357 menstrual cycle disturbances. As can be seen in Figure 1 this was enough of a change
358 to push the average depression scores to mild-moderate depression, however the
359 values for anxiety remain below a clinical diagnosis. Our findings add to the growing
360 body of research on the relationship between pandemic-related stress and menstrual
361 disturbances.

362

363 *Increased menopause symptoms were associated with increased perceived stress,*
364 *anxiety and depression*

365 We also found that fewer than ten percent of postmenopausal women+ noticed
366 changes to their menopausal status during the first year of the pandemic. Those who
367 noticed changes in their status reported more menopausal symptoms, and furthermore
368 these individuals were more likely to score higher on perceived stress, depression and
369 anxiety. Perimenopause is thought to be a time of heightened risk for mental health
370 disruption (Schmidt, 2005) and those with menopausal symptoms may be at greater risk
371 to develop psychiatric disorders (Cohen et al., 2006).

372 The percentage of disturbances in reproductive symptoms was four times greater
373 in our sample of premenopausal (27.8%) compared to postmenopausal women+ (6.7%)
374 . It is not clear why this large difference occurred but may be due to age, influence of
375 stress on the HPG axis, or level of stress overall. Indeed, other studies, including data
376 from this same sample, have found that perceived stress, anxiety and depression
377 scores were reduced with increasing age (Brotto et al., 2021; Tang et al., 2022). Thus,
378 our findings of greater premenopausal versus postmenopausal disturbances aligns with
379 data indicating mental health indices were lower for older adults during the first year of
380 the pandemic (Brotto et al., 2021). Hypothalamic-pituitary-adrenal (HPA) axis activation,
381 via stress, initially stimulates, and chronic activation inhibits the HPG resulting in
382 menstrual abnormalities (Toufexis et al., 2014) and as these interactions vary across
383 age (Heck & Handa, 2019; Phumsatitpong et al., 2021), this may also explain our
384 findings as there would have been less HPA activation in the postmenopausal women+
385 in our sample. However, it is also possible that the premenopausal versus

386 postmenopausal difference was due, in part, to the differences in the question posed to
387 the two different groups, as our survey asked about menopause status rather than
388 symptoms of menopause.

389

390 *Relevance and Limitations*

391 Allostatic load, or the cumulative burden of a variety of stressors, affects
392 cardiovascular and metabolic health (Guidi et al., 2021; McEwen, 1998). However, it is
393 important to acknowledge that female-specific factors, such as menstruation and
394 menopause, are also impacted by chronic stress. Others have postulated that female
395 health is cyclical as menstrual patterns correspond to changes in immune system
396 function (Alvergne & Högqvist Tabor, 2018). Moreover, there are specific interactions
397 between gonadal hormones and immune cells (Baker et al., 2004) emphasizing
398 important crosstalk (Arambula & McCarthy, 2020). It is possible that the mechanism
399 behind stress and menstrual changes also involves glucocorticoid receptors in the
400 endometrium (Michael & Papageorghiou, 2008). Although SARS-CoV-2 infection and
401 vaccines use can also disrupt reproductive cycles in the short term (Edelman et al.,
402 2022; Lee et al., 2021), we do not believe this influenced our findings because we found
403 that the seroprevalence of previous infection in this cohort was 2.9% (Racey et al.,
404 submitted) and vaccines were not widely available to the general BC population at the
405 time of this survey.

406

407 There are limitations to our study. This was a retrospective survey that required
408 online access. However, our findings of high levels of menstrual disturbances is
409 consistent with other studies using data from menstrual tracking apps (Haile et al.,
410 2022). In our survey we did not obtain information on the normal levels of menstrual or
411 menopausal symptoms pre-COVID19 pandemic hence we are only able to cross study
412 comparisons.

413

414 This survey was limited to residents of the province of BC and our unique
415 patterns of pandemic restriction measures may have impacted results. We also asked
416 about menopausal status rather than menopausal symptoms and this may have

417 reduced responses to this population of postmenopausal people. In our survey we also
418 did not clarify why people had suppressed cycles (e.g which type of hormonal
419 contraceptives, gender affirming hormone therapy) which future studies could explore.

420
421 We cannot rule out a selection bias in this study, and it is possible that individuals
422 who experienced higher stress pre- and post pandemic were more likely to participate.
423 Similarly, those with menstrual abnormalities may be hyper-aware of their menstrual
424 cycle and led them to participate in the current study.

425

426 **Conclusions**

427 The stress associated with the pandemic has impacted both our physical and mental
428 health and our findings suggest that this includes female-specific physical health
429 characteristics. It is imperative to continue advancing the literature on external and
430 internal factors impacting women's reproductive health. Factors that can mitigate
431 against the effects of stress such as social support (Zhao et al., 2019) and exercise
432 (Belgen Kaygısız et al., 2020), which were limited during the initial phases of the
433 pandemic, may have exacerbated the negative outcomes on reproductive cycles for
434 women+. Given the lack of attention to women's health data (Rechlin et al., 2021), more
435 studies examining female-specific health indices are needed in the literature.

436

437

438 References

- 439
440
441 Alvergne, A., & Högqvist Tabor, V. (2018). Is Female Health Cyclical? Evolutionary Perspectives
442 on Menstruation. *Trends in Ecology & Evolution*, 33(6), 399–414.
443 <https://doi.org/10.1016/j.tree.2018.03.006>
- 444 Arambula, S. E., & McCarthy, M. M. (2020). Neuroendocrine-Immune Crosstalk Shapes Sex-
445 Specific Brain Development. *Endocrinology*, 161(6), bqaa055.
446 <https://doi.org/10.1210/endocr/bqaa055>
- 447 Baker, A. E., Brautigam, V. M., & Watters, J. J. (2004). Estrogen modulates microglial
448 inflammatory mediator production via interactions with estrogen receptor beta.
449 *Endocrinology*, 145(11), 5021–5032. <https://doi.org/10.1210/en.2004-0619>
- 450 Bigalke, J. A., Greenlund, I. M., & Carter, J. R. (2020). Sex differences in self-report anxiety and
451 sleep quality during COVID-19 stay-at-home orders. *Biology of Sex Differences*, 11(1), 56.
452 <https://doi.org/10.1186/s13293-020-00333-4>
- 453 Brady, E., Nielsen, M. W., Andersen, J. P., & Oertelt-Prigione, S. (2021). Lack of consideration of
454 sex and gender in COVID-19 clinical studies. *Nature Communications*, 12(1), 4015.
455 <https://doi.org/10.1038/s41467-021-24265-8>
- 456 Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. *Qualitative Research in*
457 *Psychology*, 3(2), 77–101. <https://doi.org/10.1191/1478088706qp063oa>
- 458 Brotto, L. A., Chankasingh, K., Baaske, A., Albert, A., Booth, A., Kaida, A., Smith, L. W., Racey, S.,
459 Gottschlich, A., Murray, M. C. M., Sadarangani, M., Ogilvie, G. S., & Galea, L. (2021). *The*
460 *influence of sex, gender, age, and ethnicity on psychosocial factors and substance use*

- 461 throughout phases of the COVID-19 pandemic (p. 2021.06.08.21258572). medRxiv.
462 <https://doi.org/10.1101/2021.06.08.21258572>
- 463 Buran, G., & Gerçek Öter, E. (2022). Impact of the awareness and fear of COVID-19 on
464 menstrual symptoms in women: A cross-sectional study. *Health Care for Women*
465 *International*, 43(4), 413–427. <https://doi.org/10.1080/07399332.2021.2004149>
- 466 Ciarambino, T., Para, O., & Giordano, M. (2021). Immune system and COVID-19 by sex
467 differences and age. *Women's Health (London, England)*, 17, 17455065211022262.
468 <https://doi.org/10.1177/17455065211022262>
- 469 Cohen, L. S., Soares, C. N., Vitonis, A. F., Otto, M. W., & Harlow, B. L. (2006). Risk for New Onset
470 of Depression During the Menopausal Transition: The Harvard Study of Moods and
471 Cycles. *Archives of General Psychiatry*, 63(4), 385–390.
472 <https://doi.org/10.1001/archpsyc.63.4.385>
- 473 Connor, J., Madhavan, S., Mokashi, M., Amanuel, H., Johnson, N. R., Pace, L. E., & Bartz, D.
474 (2020). Health risks and outcomes that disproportionately affect women during the
475 Covid-19 pandemic: A review. *Social Science & Medicine (1982)*, 266, 113364.
476 <https://doi.org/10.1016/j.socscimed.2020.113364>
- 477 Core Team, R. (2022). *R: A language and environment for statistical computing*. R Foundation
478 for Statistical Computing Vienna, Austria. <https://www.r-project.org/>
- 479 Demir, O., Sal, H., & Comba, C. (2021). Triangle of COVID, anxiety and menstrual cycle. *Journal*
480 *of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and*
481 *Gynaecology*, 41(8), 1257–1261. <https://doi.org/10.1080/01443615.2021.1907562>
- 482 Edelman, A., Boniface, E. R., Benhar, E., Han, L., Matteson, K. A., Favaro, C., Pearson, J. T., &

- 483 Darney, B. G. (2022). Association Between Menstrual Cycle Length and Coronavirus
484 Disease 2019 (COVID-19) Vaccination: A U.S. Cohort. *Obstetrics & Gynecology*,
485 10.1097/AOG.0000000000004695. <https://doi.org/10.1097/AOG.0000000000004695>
- 486 Guidi, J., Lucente, M., Sonino, N., & Fava, G. A. (2021). Allostatic Load and Its Impact on Health:
487 A Systematic Review. *Psychotherapy and Psychosomatics*, 90(1), 11–27.
488 <https://doi.org/10.1159/000510696>
- 489 Haile, L., van de Roemer, N., Gemzell-Danielsson, K., Perelló Capó, J., Lete Lasa, I., Vannuccini,
490 S., Koch, M. C., Hildebrandt, T., & Calaf, J. (2022). The global pandemic and changes in
491 women’s reproductive health: An observational study. *The European Journal of*
492 *Contraception & Reproductive Health Care*, 0(0), 1–5.
493 <https://doi.org/10.1080/13625187.2021.2024161>
- 494 Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research
495 electronic data capture (REDCap)—A metadata-driven methodology and workflow
496 process for providing translational research informatics support. *Journal of Biomedical*
497 *Informatics*, 42(2), 377–381. <https://doi.org/10.1016/j.jbi.2008.08.010>
- 498 Heck, A. L., & Handa, R. J. (2019). Sex differences in the hypothalamic-pituitary-adrenal axis’
499 response to stress: An important role for gonadal hormones.
500 *Neuropsychopharmacology: Official Publication of the American College of*
501 *Neuropsychopharmacology*, 44(1), 45–58. <https://doi.org/10.1038/s41386-018-0167-9>
- 502 Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008). The link between
503 childhood trauma and depression: Insights from HPA axis studies in humans.
504 *Psychoneuroendocrinology*, 33(6), 693–710.

- 505 <https://doi.org/10.1016/j.psyneuen.2008.03.008>
- 506 Huang, F. Y., Chung, H., Kroenke, K., Delucchi, K. L., & Spitzer, R. L. (2006). Using the patient
507 health questionnaire-9 to measure depression among racially and ethnically diverse
508 primary care patients. *Journal of General Internal Medicine*, 21(6), 547–552.
- 509 Hunt, C., Gibson, G. C., Vander Horst, A., Cleveland, K. A., Wawrosch, C., Granot, M., Kuhn, T.,
510 Woolverton, C. J., & Hughes, J. W. (2021). Gender diverse college students exhibit higher
511 psychological distress than male and female peers during the novel coronavirus (COVID-
512 19) pandemic. *Psychology of Sexual Orientation and Gender Diversity*, 8(2), 238–244.
513 <https://doi.org/10.1037/sgd0000461>
- 514 Kujawa, A., Green, H., Compas, B. E., Dickey, L., & Pegg, S. (2020). Exposure to COVID-19
515 pandemic stress: Associations with depression and anxiety in emerging adults in the
516 United States. *Depression and Anxiety*, 37(12), 1280–1288.
517 <https://doi.org/10.1002/da.23109>
- 518 Lee, K. M., Junkins, E. J., Fatima, U. A., Cox, M. L., & Clancy, K. B. (2021). *Characterizing*
519 *menstrual bleeding changes occurring after SARS-CoV-2 vaccination* (p.
520 2021.10.11.21264863). medRxiv. <https://doi.org/10.1101/2021.10.11.21264863>
- 521 Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W., & Herzberg, P. Y. (2008).
522 Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in
523 the general population. *Medical Care*, 266–274.
- 524 Male, V. (2021). Menstrual changes after covid-19 vaccination. *BMJ*, 374, n2211.
525 <https://doi.org/10.1136/bmj.n2211>
- 526 McEwen, B. S. (1998). Stress, adaptation, and disease. Allostasis and allostatic load. *Annals of*

- 527 *the New York Academy of Sciences*, 840, 33–44. <https://doi.org/10.1111/j.1749->
- 528 6632.1998.tb09546.x
- 529 McEwen, B. S., & Akil, H. (2020). Revisiting the Stress Concept: Implications for Affective
- 530 Disorders. *Journal of Neuroscience*, 40(1), 12–21.
- 531 <https://doi.org/10.1523/JNEUROSCI.0733-19.2019>
- 532 Michael, A. E., & Papageorghiou, A. T. (2008). Potential significance of physiological and
- 533 pharmacological glucocorticoids in early pregnancy. *Human Reproduction Update*, 14(5),
- 534 497–517. <https://doi.org/10.1093/humupd/dmn021>
- 535 Montano, L. T., & Acebes, K. M. L. (2020). Covid stress predicts depression, anxiety and stress
- 536 symptoms of Filipino respondents. *International Journal of Research in Business and*
- 537 *Social Science*, 9(4), 78–103. <https://doi.org/10.20525/ijrbs.v9i4.773>
- 538 Nagma, S., Kapoor, G., Bharti, R., Batra, A., Batra, A., Aggarwal, A., & Sablok, A. (2015). To
- 539 Evaluate the Effect of Perceived Stress on Menstrual Function. *Journal of Clinical and*
- 540 *Diagnostic Research*: JCDR, 9(3), QC01–QC03.
- 541 <https://doi.org/10.7860/JCDR/2015/6906.5611>
- 542 Nosek, M., Kennedy, H. P., Beyene, Y., Taylor, D., Gilliss, C., & Lee, K. (2010). The effects of
- 543 perceived stress and attitudes toward menopause and aging on symptoms of
- 544 menopause. *Journal of Midwifery & Women's Health*, 55(4), 328–334.
- 545 <https://doi.org/10.1016/j.jmwh.2009.09.005>
- 546 Ogilvie, G. S., Gordon, S., Smith, L. W., Albert, A., Racey, C. S., Booth, A., Gottschlich, A.,
- 547 Goldfarb, D., Murray, M. C. M., Galea, L. A. M., Kaida, A., Brotto, L. A., & Sadarangani, M.
- 548 (2021). Intention to receive a COVID-19 vaccine: Results from a population-based survey

- 549 in Canada. *BMC Public Health*, 21(1), 1017. [https://doi.org/10.1186/s12889-021-11098-](https://doi.org/10.1186/s12889-021-11098-9)
- 550 9
- 551 Ozimek, N., Velez, K., Anvari, H., Butler, L., Goldman, K. N., & Weitowich, N. C. (2022). Impact of
- 552 stress on menstrual cyclicity during the coronavirus disease 2019 pandemic: A survey
- 553 study. *Journal of Women's Health*, 31(1), 84–90.
- 554 Phelan, N., Behan, L. A., & Owens, L. (2021). The Impact of the COVID-19 Pandemic on
- 555 Women's Reproductive Health. *Frontiers in Endocrinology*, 12, 642755.
- 556 <https://doi.org/10.3389/fendo.2021.642755>
- 557 Phumsatitpong, C., Wagenmaker, E. R., & Moenter, S. M. (2021). Neuroendocrine interactions
- 558 of the stress and reproductive axes. *Frontiers in Neuroendocrinology*, 63, 100928.
- 559 <https://doi.org/10.1016/j.yfrne.2021.100928>
- 560 Pieh, C., Budimir, S., & Probst, T. (2020). The effect of age, gender, income, work, and physical
- 561 activity on mental health during coronavirus disease (COVID-19) lockdown in Austria.
- 562 *Journal of Psychosomatic Research*, 136, 110186.
- 563 <https://doi.org/10.1016/j.jpsychores.2020.110186>
- 564 Racey, C., Booth, A., Albert, A., Smith, L., Krajdén M, M. M., Côté, H., Gottschlich, A.,
- 565 Sadarangani, A., Galea, L., Kaida, A., Brotto, L., & Ogilvie, G. ((Submitted)). Seropositivity
- 566 of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: Cross-sectional
- 567 survey with dried blood spot samples. *BMJ Open*.
- 568 Rechlin, R. K., Splinter, T. F., Hodges, T. E., Albert, A. Y., & Galea, L. A. (2021). Harnessing the
- 569 power of sex differences: What a difference ten years did not make. *BioRxiv*.
- 570 Salari, N., Hosseini-Far, A., Jalali, R., Vaisi-Raygani, A., Rasoulpoor, S., Mohammadi, M.,

- 571 Rasoulpoor, S., & Khaledi-Paveh, B. (2020). Prevalence of stress, anxiety, depression
572 among the general population during the COVID-19 pandemic: A systematic review and
573 meta-analysis. *Globalization and Health*, 16(1), 57. [https://doi.org/10.1186/s12992-020-](https://doi.org/10.1186/s12992-020-00589-w)
574 00589-w
- 575 Schmidt, P. J. (2005). Mood, depression, and reproductive hormones in the menopausal
576 transition. *The American Journal of Medicine*, 118(12, Supplement 2), 54–58.
577 <https://doi.org/10.1016/j.amjmed.2005.09.033>
- 578 Sharp, G. C., Fraser, A., Sawyer, G., Kountourides, G., Easey, K. E., Ford, G., Olszewska, Z., Howe,
579 L. D., Lawlor, D. A., Alvergne, A., & Maybin, J. A. (2021). The COVID-19 pandemic and the
580 menstrual cycle: Research gaps and opportunities. *International Journal of*
581 *Epidemiology*, dyab239. <https://doi.org/10.1093/ije/dyab239>
- 582 Solomon, C. G., Hu, F. B., Dunaif, A., Rich-Edwards, J. E., Stampfer, M. J., Willett, W. C., Speizer,
583 F. E., & Manson, J. E. (2002). Menstrual Cycle Irregularity and Risk for Future
584 Cardiovascular Disease. *The Journal of Clinical Endocrinology & Metabolism*, 87(5),
585 2013–2017. <https://doi.org/10.1210/jcem.87.5.8471>
- 586 Souza, F. A. C., Dias, R., Fernandes, C. E., Pimentel, F., & Dias, D. (2010). Menstrual irregularity:
587 A possible clinical marker of metabolic dysfunction in women with class III obesity.
588 *Gynecological Endocrinology*, 26(10), 768–772.
589 <https://doi.org/10.3109/09513590.2010.487603>
- 590 Spitzer, R. L., Kroenke, K., Williams, J. B., & Löwe, B. (2006). A brief measure for assessing
591 generalized anxiety disorder: The GAD-7. *Archives of Internal Medicine*, 166(10), 1092–
592 1097.

- 593 Tang, Q., Wang, Y., Li, J., Luo, D., Hao, X., & Xu, J. (2022). Effect of Repeated Home Quarantine
594 on Anxiety, Depression, and PTSD Symptoms in a Chinese Population During the COVID-
595 19 Pandemic: A Cross-sectional Study. *Frontiers in Psychiatry, 13*.
596 <https://www.frontiersin.org/article/10.3389/fpsyt.2022.830334>
- 597 Thurston, R. C., Aizenstein, H. J., Derby, C. A., Sejdić, E., & Maki, P. M. (2016). Menopausal Hot
598 Flashes and White Matter Hyperintensities. *Menopause (New York, N.Y.), 23*(1), 27–32.
599 <https://doi.org/10.1097/GME.0000000000000481>
- 600 Toufexis, D., Rivarola, M. A., Lara, H., & Viau, V. (2014). Stress and the Reproductive Axis.
601 *Journal of Neuroendocrinology, 26*(9), 573–586. <https://doi.org/10.1111/jne.12179>
- 602 Trogstad, L. (2022). *Increased Occurrence of Menstrual Disturbances in 18- to 30-Year-Old*
603 *Women after COVID-19 Vaccination* (SSRN Scholarly Paper ID 3998180). Social Science
604 Research Network. <https://doi.org/10.2139/ssrn.3998180>
- 605 Viau, V. (2002). Functional Cross-Talk Between the Hypothalamic-Pituitary-Gonadal and -
606 Adrenal Axes. *Journal of Neuroendocrinology, 14*(6), 506–513.
607 <https://doi.org/10.1046/j.1365-2826.2002.00798.x>
- 608 Weidner, K., Bittner, A., Beutel, M., Goeckenjan, M., Brähler, E., & Garthus-Niegel, S. (2020).
609 The role of stress and self-efficacy in somatic and psychological symptoms during the
610 climacteric period—Is there a specific association? *Maturitas, 136*, 1–6.
611 <https://doi.org/10.1016/j.maturitas.2020.03.004>
- 612 Yamamoto, K., Okazaki, A., Sakamoto, Y., & Funatsu, M. (2009). The relationship between
613 premenstrual symptoms, menstrual pain, irregular menstrual cycles, and psychosocial
614 stress among Japanese college students. *Journal of Physiological Anthropology, 28*(3),

615 129–136. <https://doi.org/10.2114/jpa2.28.129>

616 Yu, M., Han, K., & Nam, G. E. (2017). The association between mental health problems and

617 menstrual cycle irregularity among adolescent Korean girls. *Journal of Affective*

618 *Disorders*, 210, 43–48. <https://doi.org/10.1016/j.jad.2016.11.036>

619

620 **Table 1.** Demographic characteristics of respondents.
 621 + denotes GenderQueer, Agender, Two-Spirit, other
 622

Age	Menstruation Changes			P-value	Postmenopausal Changes			
	Total	No	Yes		Total	No	Yes	P-value
	No. 1,866	No. 1,347	No. 519		No. 2,305	No. 2,150	No. 155	
25-29	183 (9.8%)	127 (9.4%)	56 (10.8%)	0.14	5 (0.2%)	4 (0.2%)	1 (0.6%)	< 0.0001
30-39	627 (33.6%)	446 (33.1%)	181 (34.9%)		38 (1.6%)	34 (1.6%)	4 (2.6%)	
40-49	808 (43.3%)	602 (44.7%)	206 (39.7%)		174 (7.5%)	151 (7.0%)	23 (14.8%)	
50-59	242 (13.0%)	166 (12.3%)	76 (14.6%)		948 (41.1%)	854 (39.7%)	94 (60.6%)	
60-69	6 (0.3%)	6 (0.4%)	0 (0.0%)		1,140 (49.5%)	1,107 (51.5%)	33 (21.3%)	
Gender								
Woman	1,837 (98.4%)	1,333(99.0%)	504 (97.1%)	0.006	2,283 (99.0%)	2,130 (99.1%)	153 (98.7%)	0.49
Man	1 (0.1%)	1 (0.1%)	0 (0.0%)		3 (0.1%)	3 (0.1%)	0 (0.0%)	
Non-Binary, GenderQueer, Agender, Two-spirit or other	28 (1.5%)	13 (1.0%)	15 (2.9%)		19 (0.8%)	17 (0.8%)	2 (1.3%)	
Indigenous								
Indigenous	72 (3.9%)	47 (3.5%)	25 (4.8%)	0.35	52 (2.3%)	47 (2.2%)	5 (3.2%)	0.047
Not Indigenous	1,706 (91.4%)	1,235 (91.7%)	471 (90.8%)		2,147 (93.1%)	2,008 (93.4%)	139 (89.7%)	
Prefer not to answer	19 (1.0%)	15 (1.1%)	4 (0.8%)		13 (0.6%)	10 (0.5%)	3 (1.9%)	
Missing	69 (3.7%)	50 (3.7%)	19 (3.7%)		93 (4.0%)	85 (4.0%)	8 (5.2%)	
Latin American								
Latin American	40 (2.1%)	25 (1.9%)	15 (2.9%)	0.21	21 (0.9%)	18 (0.8%)	3 (1.9%)	0.16
Not	1,819 (97.5%)	1,316 (97.7%)	503 (96.9%)		2,267 (98.4%)	2,118 (98.5%)	149 (96.1%)	
Missing	7 (0.4%)	6 (0.4%)	1 (0.2%)			14 (0.7%)	3 (1.9%)	

					17 (0.7%)			
South Asian								
Not	1,800 (96.5%)	1,295 (96.1%)	505 (97.3%)	0.38	2,258 (98.0%)	2,112 (98.2%)	146 (94.2%)	0.012
South Asian	59 (3.2%)	46 (3.4%)	13 (2.5%)		30 (1.3%)	24 (1.1%)	6 (3.9%)	
Missing	7 (0.4%)	6 (0.4%)	1 (0.2%)		17 (0.7%)	14 (0.7%)	3 (1.9%)	
Black								
Black	19 (1.0%)	15 (1.1%)	4 (0.8%)	0.61	8 (0.3%)	8 (0.4%)	0 (0.0%)	1
Not Black	1,840 (98.6%)	1,326 (98.4%)	514 (99.0%)		2,280 (98.9%)	2,128 (99.0%)	152 (98.1%)	
Missing	7 (0.4%)	6 (0.4%)	1 (0.2%)		17 (0.7%)	14 (0.7%)	3 (1.9%)	
White								
Non-White	368 (19.7%)	281 (20.9%)	87 (16.8%)	0.044	245 (10.6%)	222 (10.3%)	23 (14.8%)	0.077
White	1,491 (79.9%)	1,060 (78.7%)	431 (83.0%)		2,043 (88.6%)	1,914 (89.0%)	129 (83.2%)	
Missing	7 (0.4%)	6 (0.4%)	1 (0.2%)		17 (0.7%)	14 (0.7%)	3 (1.9%)	
Education								
More than high school	1,705 (91.4%)	1,232 (91.5%)	473 (91.1%)	0.93	1,924 (83.5%)	1,788 (83.2%)	136 (87.7%)	0.18
High school or less	159 (8.5%)	114 (8.5%)	45 (8.7%)		377 (16.4%)	358 (16.7%)	19 (12.3%)	
Missing	2 (0.1%)	1 (0.1%)	1 (0.2%)		4 (0.2%)	4 (0.2%)	0 (0.0%)	
Number of Adults in Household								
One	388 (20.8%)	273 (20.3%)	115 (22.2%)	0.65	649 (28.2%)	601 (28.0%)	48 (31.0%)	0.51
Three or more	364 (19.5%)	263 (19.5%)	101 (19.5%)		526 (22.8%)	488 (22.7%)	38 (24.5%)	
Two	1,113 (59.6%)	810 (60.1%)	303 (58.4%)		1,121 (48.6%)	1,052 (48.9%)	69 (44.5%)	
Missing	1 (0.1%)	1 (0.1%)	0 (0.0%)		9 (0.4%)	9 (0.4%)	0 (0.0%)	
Children < 5								
None	1,514 (81.1%)	1,079 (80.1%)	435 (83.8%)	0.095	2,225 (96.5%)	2,076 (96.6%)	149 (96.1%)	0.39
One	239 (12.8%)	185 (13.7%)	54 (10.4%)		23 (1.0%)	22 (1.0%)	1 (0.6%)	

Two or more	70 (3.8%)	54 (4.0%)	16 (3.1%)		14 (0.6%)	12 (0.6%)	2 (1.3%)	
Missing	43 (2.3%)	29 (2.2%)	14 (2.7%)		43 (1.9%)	40 (1.9%)	3 (1.9%)	
Children 5-17								
None	996 (53.4%)	698 (51.8%)	298 (57.4%)	0.02	1,935 (83.9%)	1,819 (84.6%)	116 (74.8%)	0.004
One	379 (20.3%)	271 (20.1%)	108 (20.8%)		201 (8.7%)	182 (8.5%)	19 (12.3%)	
Two or more	464 (24.9%)	357 (26.5%)	107 (20.6%)		121 (5.2%)	105 (4.9%)	16 (10.3%)	
Missing	27 (1.4%)	21 (1.6%)	6 (1.2%)		48 (2.1%)	44 (2.0%)	4 (2.6%)	
Chronic Health Conditions								
None	1,026 (55.0%)	776 (57.6%)	250 (48.2%)	0.0003	998 (43.3%)	944 (43.9%)	54 (34.8%)	0.029
One or more	839 (45.0%)	570 (42.3%)	269 (51.8%)		1,300 (56.4%)	1,199 (55.8%)	101 (65.2%)	
Missing	1 (0.1%)	1 (0.1%)	0 (0.0%)		7 (0.3%)	7 (0.3%)	0 (0.0%)	
Crisis score phase 1								
Mean (SD)	27.8 (±8.0)	26.6 (±7.7)	30.9 (±8.0)	< 0.0001	24.9 (±7.6)	24.6 (±7.4)	28.9 (±8.8)	< 0.0001
Missing	63 (3.4%)	51 (3.8%)	12 (2.3%)		86 (3.7%)	78 (3.6%)	8 (5.2%)	
Anxiety GAD-7 phase 1								
Mean (SD)	6.9 (±5.2)	6.2 (±4.9)	8.7 (±5.5)	< 0.0001	5.0 (±4.7)	4.8 (±4.6)	7.4 (±5.5)	< 0.0001
Missing	49 (2.6%)	40 (3.0%)	9 (1.7%)		106 (4.6%)	100 (4.7%)	6 (3.9%)	
Depression PHQ-9 phase 1								
Mean (SD)	6.5 (±5.2)	5.7 (±4.7)	8.6 (±5.9)	< 0.0001	5.0 (±4.5)	4.8 (±4.4)	7.8 (±5.7)	< 0.0001
Missing	61 (3.3%)	51 (3.8%)	10 (1.9%)		144 (6.2%)	134 (6.2%)	10 (6.5%)	

623
624
625

627 **Table 2.** Summary of free-text responses for changes noticed in menstrual cycles.
 628 Sample sizes are given and percentages of total sample are given in parentheses.
 629

Theme categories Total n = 92	Themes	Sub-themes	Participant response excerpts
Non-Pandemic related n = 29 (31.5)	Age related n = 15 (51.7)	Entering perimenopause n = 15 (51.7)	"I'm perimenopausal"; "perimenopausal, irregular, unpredictable"
	Changes to medication or contraceptives n = 6 (20.6)	Changes to birth control (patch, pill, IUD) n = 4 (13.7)	"Removed IUD so periods are balancing out"; "Started period after going off of birth control"
		Medication, supplements n = 2 (6.8)	"— I have recently stopped taking all those supplements and have noticed that my cycle in general is longer"; "Had a period when I had xxx, otherwise I haven't had a period in a while."
	Changes to reproductive system n = 8 (27.5)	Got pregnant or intended to n = 4 (13.7)	"I got pregnant in xx"; "Stopped due to positive pregnancy test"
		Hysterectomy n = 4 (13.7)	"Cycle starting to return after ablation"; "Had hysterectomy done in xx"
	Pandemic control measures n = 63 (68.4)	Cycle length/volume changes n = 57 (90.4)	Varying cycle timing (start/end) n = 33 (52.3)
Changes in Period Length n = 14 (22.2)			"Irregular. Both long and short"; "Periods have become more irregular, sometimes long, sometimes short with some spotting in between"
Volume changes (more or less bleeding) n = 10 (15.80)			"they are more variable... shorter, sometimes very light, other quite heavy and with more severe cramps"; "Short, long and light or heavy period. No idea what is happening sort of periods"
Periods are more symptomatic n = 6 (9.5)		Mood symptoms n = 3 (4.7)	"More mood swings"; "Weird timing and more moody"
		Painful n = 3 (4.7)	"Extreme cramping throughout month of April"; "Worse migraines"


630
631

632 **Table 3.** Summary of free-text responses for changes noticed in postmenopausal
 633 status. Sample sizes are given and percentages of total sample are given in
 634 parentheses.
 635

Theme categories Total n = 111	Themes	Sub-themes	Participant response excerpts
Non-pandemic related n = 22 (19.8)	Surgery n = 10 (45.4)	Hysterectomy/Ovarian cysts n = 10 (45.4)	
	Changes to medication n = 7 (31.8)	Hormone replacement therapy (HRT) changes n = 7 (31.8)	“My postmenopausal symptoms became more severe because of changes in HRT prescription.”; “...tr(ied) a few replacement medications.”
	Pre-existing conditions n = 5 (22.7)	Endometriosis and cancer n = 5 (22.7)	“I had endometrial biopsy xx procedure”; “Bleeding due to bladder cancer”
Pandemic control measures n = 89 (80.1)	Menopause symptoms have worsened n = 69 (77.5)	Hot flashes and insomnia n = 46 (51.6)	“Hot flashes- haven’t had them in years.”; “More insomnia and hot flashes, and painful dry eyes which I didn’t have before.”
		Mood symptoms n = 13 (14.6)	“Felt lonely and depressed and hopeless”; “More emotional and stronger symptoms”
		Vaginal dryness and skin irritation n = 7 (7.8)	“Vaginal dryness, painful sex, sweats”; “More skin irritation”
		Headaches/Migraines n = 2 (2.2)	“Migraine headaches, hot flashes”; “Headaches”
	Irregular changes to health n = 20 (22.4)	Bleeding/abdominal pain n = 9 (10.1)	“One episode of postmenopausal bleeding”; “Abdominal pain and cramps in middle lower area.”
		Weight changes and hair loss n = 8 (8.9)	“Slower metabolism/weight gain in different areas of body”; “More Uti’s”
		Memory loss n = 1 (1.1)	“Memory is getting bad...feeling for words often.”; “I have felt more symptoms such as brain fog and hot flashes which I assume are hormone related.”

636
 637
 638

639 **Figure 1** Changes to menstrual and menopausal status during early COVID-19
640 pandemic increased mean CoRonavlrus Health Impact survey (CRISIS) scores, anxiety
641 (GAD-7) and depression symptoms (PHQ-9) in women+. A) Mean ($\pm 95\%$ CI) CRISIS
642 scores in women+ with changes to menstrual status were 3.4 points higher. B) Mean
643 ($\pm 95\%$ CI) GAD-7 scores in women+ with changes to menstrual status were 2 points
644 higher. C) Mean ($\pm 95\%$ CI) PHQ-9 scores in women+ with changes to menstrual status
645 were 2.4 D) Mean($\pm 95\%$ CI) CRISIS scores in women+ with changes to menopausal
646 status were 2.9 points higher. E) Mean ($\pm 95\%$ CI) GAD-7 scores in women+ with
647 changes to menopausal status were 1.5 points higher. F) Mean($\pm 95\%$ CI) PHQ-9 scores
648 in women+ with changes to menopausal status were 1.8 points higher. CI=confidence
649 interval. Figure was constructed in R v.4.1.3.



650

651

652

Supplement

653

1. Are you postmenopausal (have not had a period in 1 year or more)?

654

- Yes

655

- No

656

2. [If “No” to question 1] Since the COVID-19 pandemic and subsequent public

657

health measures in mid-March 2020, have you noticed any changes to your

658

menstrual cycle?

659

- Yes

660

- No

661

- Not applicable: I have a suppressed menstrual cycle due to hormonal

662

contraception, breast feeding, a medical condition, etc.

663

- Not applicable: other

664

3. [If “yes” to question 2] What changes have you noticed to your menstrual cycle?

665

- Periods have gotten shorter

666

- Periods have gotten longer

667

- Periods are more symptomatic (painful, more bleeding, etc.)

668

- Periods are less symptomatic

669

- More periods than normal

670

- Fewer periods than normal

671

- Other

672

4. [If “other” to question 3] What other changes in your menstrual cycle have you

673

noticed since COVID-19?

674 5. [If “yes” to question 1] Have you noticed any changes to your postmenopausal
675 status since mid-March 2020?

676 • Yes

677 • No

678 6. [If “yes” to question 5] What changes have you noticed?

679 • Started bleeding again

680 • More menstrual symptoms

681 • Other

682 7. [If “other” to question 6] Please specify the "Other" changes you have
683 experienced in your postmenopausal status

684

685

686

687